Fulcrum Therapeutics (NASDAQ:FULC – Get Free Report) was downgraded by equities researchers at JPMorgan Chase & Co. from an “overweight” rating to an “underweight” rating in a research report issued to clients and investors on Wednesday.
Several other analysts have also weighed in on FULC. Truist Financial lowered shares of Fulcrum Therapeutics from a “buy” rating to a “hold” rating and set a $4.00 target price on the stock. in a research report on Tuesday. HC Wainwright lowered shares of Fulcrum Therapeutics from a “buy” rating to a “neutral” rating and set a $3.00 target price on the stock. in a research report on Tuesday. Leerink Partners lowered shares of Fulcrum Therapeutics from an “outperform” rating to a “market perform” rating and set a $4.00 target price on the stock. in a research report on Tuesday. Jefferies Financial Group set a $4.00 target price on shares of Fulcrum Therapeutics in a research report on Tuesday. Finally, Wall Street Zen upgraded shares of Fulcrum Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 2nd. One equities research analyst has rated the stock with a Buy rating, seven have given a Hold rating and four have assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Reduce” and a consensus target price of $8.20.
Check Out Our Latest Report on Fulcrum Therapeutics
Fulcrum Therapeutics Stock Performance
Fulcrum Therapeutics (NASDAQ:FULC – Get Free Report) last posted its quarterly earnings data on Monday, April 27th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.06. Equities analysts predict that Fulcrum Therapeutics will post -1.16 EPS for the current year.
Hedge Funds Weigh In On Fulcrum Therapeutics
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. acquired a new position in Fulcrum Therapeutics in the fourth quarter valued at about $30,000. Meeder Asset Management Inc. acquired a new position in Fulcrum Therapeutics in the fourth quarter valued at about $39,000. Quarry LP acquired a new position in Fulcrum Therapeutics in the third quarter valued at about $35,000. Persistent Asset Partners Ltd bought a new position in shares of Fulcrum Therapeutics in the fourth quarter worth about $75,000. Finally, Summit Securities Group LLC bought a new position in shares of Fulcrum Therapeutics in the first quarter worth about $53,000. 89.83% of the stock is currently owned by institutional investors and hedge funds.
Key Headlines Impacting Fulcrum Therapeutics
Here are the key news stories impacting Fulcrum Therapeutics this week:
- Negative Sentiment: Fulcrum halted its pociredir program after FDA feedback raised serious safety concerns, wiping out its lead clinical asset and prompting a strategic review that could include a sale or merger. Reuters: Fulcrum scraps sickle cell drug program after FDA raises cancer-risk concerns
- Negative Sentiment: Multiple law firms launched investigations into whether Fulcrum and its executives violated securities laws after the stock’s steep drop, adding legal overhang and investor uncertainty. PR Newswire: Fulcrum Therapeutics, Inc. Investigation Initiated
- Negative Sentiment: Several analysts cut ratings, including downgrades from Cantor Fitzgerald, Leerink Partners, Stifel, and HC Wainwright, reflecting a sharply less optimistic outlook after the program termination. Tickerreport.com: Fulcrum Therapeutics was downgraded by Cantor Fitzgerald
About Fulcrum Therapeutics
Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.
Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.
Read More
- Five stocks we like better than Fulcrum Therapeutics
- MongoDB Is the Latest SaaS Apocalypse Victim to Say “Not Today”
- Urban Outfitters Stock Stalls Despite Another Strong Quarter
- Berkshire Builds a Moat Around Homebuilders
- Tomato Prices Are Spiking, and These 2 Food Stocks Could Feel the Squeeze
Receive News & Ratings for Fulcrum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulcrum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
